Bolt Biotherapeutics (BOLT) closed at $6.27 on October 23, 2026, up 49.6% from the previous close, on volume of 12,677,629 shares (30-day average 33,741).
Data as of October 23, 2026.
Why Is Penny Stock Bolt Biotherapeutics (BOLT) Up 62% Today?
TipRanks (Fri, 23-Oct 2:19 PM ET)
Bolt Biotherapeutics Completes Prana Merger, Refocuses Pipeline
TipRanks (Fri, 23-Oct 11:28 AM ET)
Market Chameleon (Fri, 23-Oct 6:25 AM ET)
Globe Newswire (Fri, 23-Oct 9:08 AM ET)
Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Tue, 11-Aug 4:05 PM ET)
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
Bolt Biotherapeutics trades on the NASDAQ stock market under the symbol BOLT.
As of October 23, 2026, BOLT stock price climbed to $6.27 with 12,677,629 million shares trading.
BOLT has a beta of 0.53, meaning it tends to be less sensitive to market movements. BOLT has a correlation of 0.01 to the broad based SPY ETF.
BOLT has a market cap of $12.08 million. This is considered a Sub-Micro Cap stock.
Last quarter Bolt Biotherapeutics reported $5,000 in Revenue and -$4.57 earnings per share. This fell short of revenue expectation by $-695,000 and exceeded earnings estimates by $12.87.
In the last 3 years, BOLT traded as high as $31.20 and as low as $3.10.
The top ETF exchange traded funds that BOLT belongs to (by Net Assets): VXF.
BOLT has underperformed the market in the last year with a return of +8.9%, while SPY returned +14.3%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in BOLT shares. However, BOLT has outperformed the market in the last 3 month and 2 week periods, returning +64.6% and +52.6%, while SPY returned +3.2% and -2.4%, respectively. This indicates BOLT has been having a stronger performance recently.
BOLT support price is $3.88 and resistance is $4.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BOLT shares will trade within this expected range on the day.
